T-SPOT.TB TEST
Oxford Immunotec, Ltd. · Decision date Aug 4, 2025
What did the FDA approve?
FDA records P070006/S027 as a supplement to PMA P070006, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 4, 2025.
FDA approval order statement
Approval for three changes to the T-Cell Select reagent kit: to change the concentration of one antibody reagent, to add an alternative supplier of both antibody reagents, and to extend the open container shelf life.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Microbiology
- Decision date
- Aug 4, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P070006/S027
- Regulatory pathway
- PMA supplement
- Applicant
- Oxford Immunotec, Ltd.
- Product code
- OJN
- Decision code
- APPR
- Decision date
- Aug 4, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mycobacterium tuberculosis, Cell mediated immune response, enzyme-linked immunospot test.
- Applicant
- Oxford Immunotec, Ltd.
- Product code
- OJN
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P070006/S027 received
Application receipt date recorded by FDA.
P070006/S028 · Related supplement
T-SPOT.TB Test
P070006/S027 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P070006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
T-SPOT.TB TestP070006/S028 | Oxford Immunotec, Ltd. | PMA supplement | Aug 4, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Oxford Immunotec, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 94c Innovation Dr., Milton Park, Abingdon Oxfordshire, OX14 4RZ
Sources and methodology
- Original FDA record: P070006/S027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records